FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011
FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
Absent mature data suggesting that Genentech's biomarker strategy would likely prove Avastin's efficacy in a subpopulation, ODAC members did not want to expose patients unnecessarily to a toxic agent for many years to come.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Despite Passionate Patient Accounts, FDA Sees No Evidence of 'Super-Responders' in Avastin Trials
June 29, 2011 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
March 2, 2011 / Pharmacogenomics Reporter - NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
February 23, 2011 / Pharmacogenomics Reporter - Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?
December 22, 2010 / Pharmacogenomics Reporter